Celldex Therapeutics reported $511.25M in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
AbbVie USD 136.46B 2.5B Mar/2026
Agenus USD 186.46M 40.34M Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
Bristol-Myers Squibb USD 86.48B 3.56B Mar/2026
Celldex Therapeutics USD 511.25M 71.73M Mar/2026
Glaxosmithkline GBP 82.34B 102.25M Dec/2025
Nektar Therapeutics USD 280.41M 20.94M Dec/2025
Northwest Biotherapeutics USD 30.61M 1.06M Sep/2025
Pfizer USD 207.62B 542M Mar/2026
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Roche Holding CHF 100.7B 5.94B Dec/2025